共 68 条
[11]
Proverbs-Singh TA(2018)Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer JAMA Oncol 4 374-378
[12]
Postow MA(2016)Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer Oncoimmunology 5 e1231292-1380
[13]
Fujimoto D(2008)Lung cancer N Engl J Med 359 1367-567
[14]
Garassino MC(2014)Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 563-1550
[15]
Garcia S(2016)Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 387 1540-1368
[16]
Garon EB(2012)Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab J Thorac Oncol 7 1361-e358
[17]
Gauvain C(2018)Real-world efficacy and safety of nivolumab for advanced non-small-cell lung cancer: a retrospective multicenter analysis Clin Lung Cancer 19 e349-407
[18]
Haratani K(2017)Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis J Thorac Oncol 12 403-15046
[19]
Hasan Ali O(2016)The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures Oncotarget 7 15033-589
[20]
Herbst RS(2018)Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: open-label, phase 3 KEYNOTE-042 study J Clin Oncol 36 abstr LBA4-1833